ION Breast Cancer Clinical Pathways - ION Solutions

More documents

Recommendations

Info

Anti-EmeticsEmetogenic Risk:High Emetic Risk5HT3 or palonosetron hydrochloride; steroid: and aprepitant or fosaprepitantModerate Emetic Risk5HT3 or palonosetron hydrochloride: steroid; +/- aprepitant or fosaprepitantLow Emetic RiskGeneric ondansetron or granisetronMinimal Emetic RiskAgent as listed belowMetaclopramide, lorazepam, prochlorazepine, h2 Blocker or proton pump inhibitor, steroidsand other non-5HT3 or non-aprepitant agents are optional and personalized.Compliance is only for the first cycle of any new line of treatment for chemotherapy forbreast, colon or lung.WBC SupportFebrile Neutropenia Risk:Febrile Neutropenia Risk ˃20%Administer CSFFebrile Neutropenia Risk 65, previous chemotherapy or radiationtherapy, poor performance status, renal or liver impairment, open wounds, preexistingneutropenia, bone marrow metastasis) with documentation.Compliance is only for the first cycle of any new line of treatment for chemotherapy forbreast, colon or lung.Page 36 of 39© 2013 by ION Solutions. All rights reserved
Breast CancerColon CancerPage 37 of 39© 2013 by ION Solutions. All rights reserved
Page 1 and 2: ION SolutionsNational Physician Net
Page 3: Best Supportive Care and/or Hospice
Page 6 and 7: Chemotherapy:Taxotere (Docetaxel) A
Page 8 and 9: Taxotere (Docetaxel) Paraplatin (Ca
Page 10 and 11: Taxotere (Docetaxel) EP=Low; FN=10%
Page 12 and 13: Herceptin (Trastuzumab) Followed by
Page 14 and 15: Herceptin (Trastuzumab) Taxotere (D
Page 16 and 17: Colon: First Line MetastaticChemoth
Page 18 and 19: 5-FU (5-Fluorouracil) Leucovorin +/
Page 20 and 21: Note: Wild Type KRAS documentation
Page 22 and 23: Camptosar (Irinotecan) Avastin (Bev
Page 24 and 25: Adjuvant Non-Small Cell Lung (NSCL)
Page 26 and 27: Paraplatin (Carboplatin) Taxotere (
Page 28 and 29: Best Supportive Care and/or Hospice
Page 30 and 31: Clinical Trial:Screen patient for c
Page 32 and 33: Small Cell Lung: Extensive Disease
Page 34 and 35: Paraplatin (Carboplatin) VP-16 (Eto
Page 38 and 39: Lung CancerPage 38 of 39© 2013 by

ION Breast Cancer Clinical Pathways - ION Solutions

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?